Stocks to Watch: Gemini Explorations, Inc. (OTCBB: GXPI), BodyTel Scientific Inc. (OTC BB:BDYT) , Eugene Science Inc. (OTC BB:EUSI.OB) , Oramed Pharmaceuticals Inc. (OTCBB: ORMP), AmeriChip International Inc. (OTC BB:ACII)
Featured Stock: Gemini Explorations, Inc.
(OTCBB: GXPI)
Current Price (0.16)
http://www.wallstreetstockreview.com/
New Research Issued on Gemini Explorations by Beacon Equity Research
The full report is available at http://www.BeaconEquityResearch.com
Anyone interested in receiving alerts regarding Gemini Explorations research should email members@beaconequityresearch.com with “GXPI” in the subject line.
In the report, the analyst writes, “Gemini Explorations, Inc. (GXPI) is an emerging mining company focused on exploring, developing and mining gold properties. The Company’s main projects are located in the heart of
“The Company’s Los Chorros Project is at present a producing gold mine with a low recovery rate and operating capacity due to outdated equipment. Gemini Explorations has undertaken a modernization program to expand Los Chorros production capacity to approximately 100 tons of ore per day in the first year of operation. At these levels of production plus the estimated gold yields of 20 grams per ton of ore, the Company should report monthly revenue of approximately $1.5 million and operating cash flows of up to $1.1 million in less than one year.”
Other companies in the gold sector include Barrick Gold Corp. (NYSE: ABX), Goldcorp Inc. (NYSE: GG) Pacific Gold Corp. (OTCBB: PCFG) and Silverado Gold Mines (OTCBB: SLGLF).
Beacon Equity Research Disclosure
The analysts contributing to this report do not hold any shares of Gemini Explorations (GXPI). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research (“Beacon”) certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon Equity Research has been compensated a total of fifty thousand dollars by Caroline Industries and six thousand five hundred dollars from Equity Alliance for enrollment of GXPI in its research program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
SOURCE: Gemini Explorations
Beacon Equity Research
Jeff Bishop, 469-361-6239
editor@beaconequityresearch.com
http://www.beaconequityresearch.com/
or
Gemini Explorations
Michael Hill
1 877 700 1644
For an in-depth analyst report, please visit: www.WallstreetStockReview.com
BodyTel Scientific Inc.
(OTC BB:BDYT)
Current Price (2.74)
HENDERSON, Nev., Nov. 15, 2007 -- BodyTel Scientific, Inc. (OTC BB:BDYT.OB - News), a developer of wireless telemedical measuring devices, announced that it has set the initial production number of its blood glucose meter, GlucoTel, to 350,000 units for calendar year 2008. The units are expected to be available in countries requiring the CE approval during the first quarter 2008 and are expected to be on sale in countries requiring FDA certification during the second quarter of 2008. In anticipation of the market launch, BodyTel has submitted design and utility patents for the worldwide intellectual property protection of GlucoTel. BodyTel Scientific Inc. is a German-American Telehealth company that specializes in telemedical monitoring and management systems for chronic illnesses. The company combines their know-how in telecommunications, internet and medical technology to create new products and services for the changing needs of global health.
Eugene Science Inc.
(OTC BB:EUSI.OB)
Current Price (2.76)
LOS ANGELES, CA----Nov 15, 2007 -- Eugene Science Inc. (OTC BB:EUSI.OB - News), a leader in the nutraceutical marketplace with its cholesterol lowering CholZero (CZ(TM)) plant sterols, today announced it has appointed Andrew Altman to the newly created position of Vice President - Business Development. Based in Bucheon,
Oramed Pharmaceuticals Inc.
(OTCBB: ORMP)
Current Price (0.30)
JERUSALEM--Nov 15--Oramed Pharmaceuticals, Inc. (OTCBB:ORMP - News) (http://www.oramed.com), a developer of oral delivery systems, is pleased to announce that it has successfully completed animal studies as part of Phase 1B clinical trials for its oral insulin capsule. These positive results follow the successful completion of a Phase 1A study on eight healthy volunteers. The Phase 1B study was intended to assess the optimization of dosage for the formulation of Oramed’s proprietary oral insulin delivery technology. Oramed will now move ahead with additional trials on human volunteers for the final formulation in the upcoming weeks. The company’s goal is for the completion of formal Phase 1 studies by mid-2008. Oramed Pharmaceuticals' is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally soft gel insulin capsule for the treatment of diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines. For more information on Oramed Pharmaceuticals please visit our website: http://www.oramedpharma.com
AmeriChip International Inc.
(OTC BB:ACII)
Current Price (0.03)
CLINTON TOWNSHIP, MI----Nov 15, 2007 -- AmeriChip International Inc. (OTC BB:ACII.OB - News), a leader in creating, leading and driving a new worldwide market using a patented Laser Assisted Chip Control (LACC) process for dry machining, announced today that it has been assigned a Central Contractor Registration ("CCR") number by the U.S. Federal Government. The innovative AmeriChip business model, enhanced by its AmeriChip Tool and Abrasives subsidiary, is designed to establish an extensive resource for cost saving services and products that all cost conscious industrial steel and aluminum machining companies require. AmeriChip is committed to keeping jobs in
WallStreetStockReview.com is owned and operated by Iron Consulting.
Verify all claims and do your own due diligence. Iron Consulting profiles are not a solicitation or recommendation to buy, sell or hold securities. Iron Consulting is not offering secu rities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Iron Consulting is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b),WallStreetStockReview.com is owned and operated by Iron Consulting. Iron Consulting www.ironconsultinginc.com has receive seventy two thousand dollars in 2006 and thirty six thousand in 2007 from Equity Alliance Intl. www.equityallianceir.com for a internet marketing program. Neither Iron Consulting nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Iron Consulting receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Iron Consulting statements and opinions and such statements and opinions cannot be considered independent. Iron Consulting and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements ar e made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Iron Consulting services are often paid for using free-trading shares. Iron Consulting may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
